Related Experiment Video
Updated: Sep 12, 2026
Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)
Published on: August 21, 2016
[Outcome of pregnancy with systemic lupus erythematosus treated with DNA immunoabsorbent]
Guifen Li1, Yun Zhao, Yanling Li
1Depatment of Obstetrics and Gynecology, Zibo First Hospital, Zibo, Shandong Province 255200, China.
Objective:
To study the outcome of pregnancy with systemic lupus erythematosus (SLE) treated by DNA immunoabsorbent therapy.
Methods:
Sixty nine SLE women with pregnancy were randomly enrolled into DNA immunoabsorbent group (35, group I) and common therapeutic group (34, group II) as control. Outcomes of pregnancy and complications were analyzed.
Results:
The incidence of complication and fetus loss in group I was 28.6% (10 cases) and 20.0% (7 cases), while 85.3% (29 cases) and 58.8% (20 cases) in group II, there was very significant difference respectively (P < 0.01). The incidence of premature birth was 8.6% (3 cases) in group I, 26.5% (9 cases) in group II, the difference was significant (P < 0.05).
Conclusion:
DNA immunoabsorbent was more efficient than common therapy in the management of SLE with pregnancy.
